title: Dendritic cells in clinical trials for multiple myeloma.
abstract: Due to the existence of the truly specific tumor antigen idiotype in multiple myeloma and based on encouraging data from dendritic cell vaccinated B-cell non-Hodgkin's lymphoma (NHL) patients, dendritic cell-based vaccination was first initiated in myeloma patients in 1995. This overview will summarize published and ongoing clinical trials in patients with multiple myeloma who are treated with idiotype-based dendritic cell (Id/DC) vaccination. All groups of investigators have found that Id/DC vaccination of multiple-myeloma patients is feasible and that myeloma-specific immunity can be induced in heavily pretreated individuals. In future trials, new dendritic cell-based immunization strategies will be investigated based on techniques like RNA transfection of DC.
authors.affiliation: Department of Hematology, Oncology, Immunology and Rheumatology, University of Tübingen, Tübingen, Germany.
authors.forename: Volker L
authors.initials: VL
authors.lastname: Reichardt
authors.forename: Peter
authors.initials: P
authors.lastname: Brossart
mesh_terms: D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D007167:Immunotherapy / Q000379:methods*; D009101:Multiple Myeloma / Q000276:immunology* / Q000628:therapy*; D014611:Vaccination
chemical_list: D007130:Immunoglobulin Idiotypes